TDRD7

Summary

TDRD7 (tudor domain containing 7, HGNC:30831) is a protein-coding gene on chromosome 9q22.33, encoding Tudor domain-containing protein 7 (Q8NHU6). Component of specific cytoplasmic RNA granules involved in post-transcriptional regulation of specific genes: probably acts by binding to specific mRNAs and regulating their translation.

The protein encoded by this gene belongs to the Tudor family of proteins. This protein contains conserved Tudor domains and LOTUS domains. It is a component of RNA granules, which function in RNA processing. Mutations in this gene have been associated with cataract formation in mouse and human. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 23424 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cataract 36 (Strong, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 284 total — 7 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 2
• Druggable target: yes
• MANE Select transcript: NM_014290

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30831
Approved symbol	TDRD7
Name	tudor domain containing 7
Location	9q22.33
Locus type	gene with protein product
Status	Approved
Aliases	PCTAIRE2BP
Ensembl gene	ENSG00000196116
Ensembl biotype	protein_coding
OMIM	611258
Entrez	23424

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 8 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000355295, ENST00000492428, ENST00000861597, ENST00000861598, ENST00000861599, ENST00000936488, ENST00000936489, ENST00000943578, ENST00000943579

RefSeq mRNA: 2 — MANE Select: NM_014290 NM_001302884, NM_014290

CCDS: CCDS6725

Canonical transcript exons

ENST00000355295 — 17 exons

Exon	Start	End
ENSE00000805642	97487172	97487332
ENSE00000805643	97482849	97483351
ENSE00000805644	97480828	97480938
ENSE00000805645	97478439	97478573
ENSE00000805646	97475383	97475469
ENSE00001624435	97460178	97460764
ENSE00001650004	97464842	97465028
ENSE00001723656	97439245	97439318
ENSE00001751380	97432025	97432238
ENSE00001789451	97441658	97441875
ENSE00001829042	97495663	97496125
ENSE00001919631	97412096	97412238
ENSE00002231144	97428460	97428672
ENSE00003515299	97472293	97472495
ENSE00003540266	97473492	97473626
ENSE00003647052	97430933	97431074
ENSE00003670688	97470558	97470669

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 93.77.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.9168 / max 445.3931, expressed in 1590 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
97551	6.8017	1587
97550	0.1151	53

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	93.77	gold quality
oocyte	CL:0000023	93.19	gold quality
jejunal mucosa	UBERON:0000399	92.17	gold quality
pigmented layer of retina	UBERON:0001782	90.77	gold quality
medial globus pallidus	UBERON:0002477	89.21	gold quality
sperm	CL:0000019	88.42	gold quality
globus pallidus	UBERON:0001875	88.23	gold quality
substantia nigra pars reticulata	UBERON:0001966	88.16	gold quality
monocyte	CL:0000576	88.05	gold quality
mononuclear cell	CL:0000842	87.98	gold quality
male germ cell	CL:0000015	87.78	gold quality
duodenum	UBERON:0002114	87.74	gold quality
leukocyte	CL:0000738	87.70	gold quality
adult organism	UBERON:0007023	87.16	gold quality
testis	UBERON:0000473	87.07	gold quality
middle frontal gyrus	UBERON:0002702	86.90	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.85	gold quality
left testis	UBERON:0004533	86.83	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.79	gold quality
right testis	UBERON:0004534	86.60	gold quality
spinal cord	UBERON:0002240	86.54	gold quality
rectum	UBERON:0001052	86.47	gold quality
frontal pole	UBERON:0002795	86.30	gold quality
mucosa of transverse colon	UBERON:0004991	86.30	gold quality
bronchial epithelial cell	CL:0002328	86.25	gold quality
colonic mucosa	UBERON:0000317	86.17	gold quality
jejunum	UBERON:0002115	85.77	gold quality
epithelium of bronchus	UBERON:0002031	85.76	gold quality
ileal mucosa	UBERON:0000331	85.59	gold quality
bronchus	UBERON:0002185	85.35	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting TDRD7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-6755-3P	98.61	66.90	834
HSA-MIR-5187-3P	97.28	67.10	1037
HSA-MIR-3664-5P	96.74	66.56	770

Literature-anchored findings (GeneRIF, showing 6)

• study describes 2 cases of pediatric cataract with loss-of-function mutations in TDRD7; TDRD7 coimmunoprecipitates with specific lens mRNAs; required for posttranscriptional control of mRNAs critical to normal lens development and RNA granule function (PMID:21436445)
• present study suggests that the rs10981985 G –> A variant within the TDRD7 gene may protect against cortical age-related cataract in a Han Chinese population (PMID:24435515)
• Human cataracts and the TDRD7 gene loss-of-function mutations are strongly causally related, as the expression level of plasma TDRD7 mRNA in patients with cataracts was statistically significantly lower than in the normal control group. (PMID:25120344)
• Our purpose was to uncover novel human mutations and genes causing familial nonobstructive azoospermia and congenital cataract. Two novel loss-of-function mutations (c.324_325insA (T110Nfs*30) and c.688_689insA (p.Y230X), respectively) of TDRD7 were found in the affected patients (PMID:31048812)
• The interferon-inducible protein TDRD7 inhibits AMP-activated protein kinase and thereby restricts autophagy-independent virus replication. (PMID:32273341)
• TDRD7 participates in lens development and spermiogenesis by mediating autophagosome maturation. (PMID:33618632)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tdrd7a	ENSDARG00000032808
danio_rerio	tdrd7b	ENSDARG00000077523
mus_musculus	Tdrd7	ENSMUSG00000035517
rattus_norvegicus	Tdrd7	ENSRNOG00000055779

Paralogs (6): TDRD1 (ENSG00000095627), TDRD5 (ENSG00000162782), TDRD10 (ENSG00000163239), TDRD6 (ENSG00000180113), TDRKH (ENSG00000182134), TDRD15 (ENSG00000218819)

Protein

Protein identifiers

Tudor domain-containing protein 7 — Q8NHU6 (reviewed: Q8NHU6)

Alternative names: PCTAIRE2-binding protein, Tudor repeat associator with PCTAIRE-2

All UniProt accessions (1): Q8NHU6

UniProt curated annotations — full annotation on UniProt →

Function. Component of specific cytoplasmic RNA granules involved in post-transcriptional regulation of specific genes: probably acts by binding to specific mRNAs and regulating their translation. Required for lens transparency during lens development, by regulating translation of genes such as CRYBB3 and HSPB1 in the developing lens. Also required during spermatogenesis.

Subunit / interactions. Found in a mRNP complex, at least composed of TDRD1, TDRD6, TDRD7 and DDX4. Found in a complex containing CABLES1, CDK16 and CDK17. Interacts with CABLES1, CDK17 and PIWIL1.

Subcellular location. Cytoplasm.

Disease relevance. Cataract 36 (CTRCT36) [MIM:613887] An opacification of the crystalline lens of the eye becoming evident at birth. It frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the TDRD7 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8NHU6-1	1	yes
Q8NHU6-2	2
Q8NHU6-3	3

RefSeq proteins (2): NP_001289813, NP_055105* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002999	Tudor	Domain
IPR025605	OST-HTH/LOTUS_dom	Domain
IPR035437	SNase_OB-fold_sf	Homologous_superfamily
IPR037978	TDRD7_LOTUS_3	Domain
IPR041966	LOTUS-like	Homologous_superfamily
IPR047448	Tudor_TDRD7_rpt2	Domain
IPR047449	Tudor_TDRD7_rpt3	Domain
IPR050621	Tudor_domain_containing	Family

Pfam: PF00567, PF12872

UniProt features (26 total): domain 5, region of interest 4, splice variant 3, sequence variant 3, helix 3, modified residue 2, turn 2, strand 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3RCO	X-RAY DIFFRACTION	1.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NHU6-F1	73.60	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 319, 859

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 309 (showing top): GOBP_LENS_FIBER_CELL_DIFFERENTIATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_AXIS_SPECIFICATION, GOBP_EMBRYONIC_AXIS_SPECIFICATION, GOBP_OOGENESIS, GOBP_MALE_GAMETE_GENERATION, BOYLAN_MULTIPLE_MYELOMA_D_DN, EFC_Q6, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS, GOBP_ANATOMICAL_STRUCTURE_MATURATION, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_ANTERIOR_POSTERIOR_PATTERN_SPECIFICATION, GOBP_CELL_MATURATION, GOBP_EMBRYONIC_PATTERN_SPECIFICATION

GO Biological Process (7): lens morphogenesis in camera-type eye (GO:0002089), spermatogenesis (GO:0007283), post-transcriptional regulation of gene expression (GO:0010608), P granule organization (GO:0030719), piRNA processing (GO:0034587), lens fiber cell differentiation (GO:0070306), cell differentiation (GO:0030154)

GO Molecular Function (3): mRNA binding (GO:0003729), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (4): cytoplasm (GO:0005737), chromatoid body (GO:0033391), ribonucleoprotein granule (GO:0035770), P granule (GO:0043186)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lens development in camera-type eye	2
cytoplasmic ribonucleoprotein granule	2
anatomical structure morphogenesis	1
camera-type eye morphogenesis	1
developmental process involved in reproduction	1
male gamete generation	1
regulation of gene expression	1
organelle organization	1
pole plasm assembly	1
regulatory ncRNA processing	1
epithelial cell differentiation	1
cellular developmental process	1
RNA binding	1
nucleic acid binding	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
intracellular membraneless organelle	1
supramolecular complex	1
germ plasm	1

Protein interactions and networks

STRING

1474 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TDRD7	CCDC180	Q9P1Z9	916
TDRD7	CDK17	Q00537	910
TDRD7	CABLES1	Q8TDN4	898
TDRD7	CDK18	Q07002	795
TDRD7	DND1	Q8IYX4	782
TDRD7	TDRD9	Q8NDG6	775
TDRD7	PIWIL1	Q96J94	770
TDRD7	PIWIL2	Q8TC59	769
TDRD7	NANOS1	Q8WY41	715
TDRD7	CDK16	Q00536	703
TDRD7	DDX25	Q9UHL0	672
TDRD7	MARF1	Q9Y4F3	670
TDRD7	TACC1	O75410	652
TDRD7	CRYAA	P02489	627
TDRD7	BFSP1	Q12934	620

IntAct

40 interactions, top by confidence:

A	B	Type	Score
TDRD7	GABPB1	psi-mi:“MI:0915”(physical association)	0.740
GABPB1	TDRD7	psi-mi:“MI:0915”(physical association)	0.740
PIMREG	MTA2	psi-mi:“MI:0914”(association)	0.600
TACC1	TDRD7	psi-mi:“MI:0915”(physical association)	0.580
TDRD7	TACC1	psi-mi:“MI:0915”(physical association)	0.580
TDRD7	TACC1	psi-mi:“MI:0914”(association)	0.580
CDKN2A	TDRD7	psi-mi:“MI:0915”(physical association)	0.510
TDRD7	CDKN2A	psi-mi:“MI:0915”(physical association)	0.510
TDRD7	HSPD1	psi-mi:“MI:0915”(physical association)	0.400
TDRD7	TDRD7	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	FXR1	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	NLGN3	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	SHANK3	psi-mi:“MI:0915”(physical association)	0.370
FRAT1	TDRD7	psi-mi:“MI:0915”(physical association)	0.370
BUB1	TDRD7	psi-mi:“MI:0915”(physical association)	0.370
CCND1	TDRD7	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	CTNNA1	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	DCC	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	DLC1	psi-mi:“MI:0915”(physical association)	0.370
MLH1	TDRD7	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	MLH3	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	MSH2	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	MUTYH	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	NRAS	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (69): TDRD7 (Two-hybrid), TDRD7 (Two-hybrid), TDRD7 (Affinity Capture-MS), TDRD7 (Affinity Capture-MS), TDRD7 (Affinity Capture-MS), TDRD7 (Two-hybrid), MAGEA8 (Two-hybrid), TDRD7 (Affinity Capture-MS), TDRD7 (Affinity Capture-MS), TDRD7 (Affinity Capture-MS), TDRD7 (Two-hybrid), TACC1 (Reconstituted Complex), TDRD7 (Affinity Capture-Western), CDK17 (Affinity Capture-Western), TACC1 (Affinity Capture-Western)

ESM2 similar proteins: A0JM98, A1L1H3, A6NAF9, A6QLE1, A9CPT4, B5MCY1, D2H0H6, D2H3M0, D4A7V9, E1BPH3, E1C3S7, E2QTD3, E2RDV1, E7FDW8, F1R237, O60522, P57075, P61407, P97874, Q14B46, Q1L981, Q4R3G4, Q58EK5, Q5DTW2, Q5JTW2, Q5M7P8, Q5RAH6, Q5VCS6, Q5VZ19, Q5XGX5, Q61846, Q68DX3, Q6NU04, Q80VK6, Q8K1H1, Q8NAT2, Q8NHU6, Q90WE3, Q99KY4, Q99MV1

Diamond homologs: A0JM98, A1L1H3, A6NAF9, A6QLE1, B4F7C4, D2H0H6, D2H3M0, E1BPH3, E1C3S7, E2QTD3, E2RDV1, E7FDW8, Q1L981, Q5M7P8, Q5RAH6, Q5VCS6, Q6NU04, Q8K1H1, Q8NAT2, Q8NHU6, Q9R1R4, H9JD76, Q80VL1, Q9VQ91, Q4R3G4, Q9BXT8, Q9Y2W6, Q99MV1, Q9BXT4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 33 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transcriptional Regulation by TP53	6	16.9×	3e-04
Cell Cycle	6	9.8×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

284 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	7
Likely pathogenic	2
Uncertain significance	177
Likely benign	37
Benign	26

Top pathogenic / likely-pathogenic (9)

Variant ID	HGVS	Classification
1228374	NM_014290.3(TDRD7):c.2008C>T (p.Gln670Ter)	Pathogenic
2413118	NM_014290.3(TDRD7):c.2660del (p.Lys887fs)	Pathogenic
30903	NM_014290.3(TDRD7):c.1849GTT[1] (p.Val618del)	Pathogenic
426069	NM_014290.3(TDRD7):c.1129del (p.Ala377fs)	Pathogenic
427904	NM_014290.3(TDRD7):c.689dup (p.Tyr230Ter)	Pathogenic
427905	NM_014290.3(TDRD7):c.328dup (p.Thr110fs)	Pathogenic
4720913	NM_014290.3(TDRD7):c.2823del (p.Met942fs)	Pathogenic
2505533	NM_014290.3(TDRD7):c.855G>A (p.Thr285=)	Likely pathogenic
800981	NM_014290.3(TDRD7):c.2539G>A (p.Asp847Asn)	Likely pathogenic

SpliceAI

2862 predictions. Top by Δscore:

Variant	Effect	Δscore
9:97428552:A:T	donor_gain	1.0000
9:97428595:C:G	donor_gain	1.0000
9:97464834:T:A	acceptor_gain	1.0000
9:97464841:GGTAT:G	acceptor_gain	1.0000
9:97472291:A:AG	acceptor_gain	1.0000
9:97472292:G:GG	acceptor_gain	1.0000
9:97472460:GCTA:G	donor_gain	1.0000
9:97472468:TGAC:T	donor_gain	1.0000
9:97472493:CAG:C	donor_loss	1.0000
9:97472494:AGGT:A	donor_loss	1.0000
9:97472495:GGTAC:G	donor_loss	1.0000
9:97472496:GT:G	donor_loss	1.0000
9:97472497:T:A	donor_loss	1.0000
9:97473485:GTTAT:G	acceptor_loss	1.0000
9:97473486:TTATA:T	acceptor_loss	1.0000
9:97473487:TATAG:T	acceptor_loss	1.0000
9:97473488:ATAGG:A	acceptor_loss	1.0000
9:97473489:TAGGT:T	acceptor_loss	1.0000
9:97473491:G:C	acceptor_loss	1.0000
9:97473623:CAAGG:C	donor_loss	1.0000
9:97473624:AAG:A	donor_loss	1.0000
9:97473625:AGGT:A	donor_loss	1.0000
9:97473626:GGTAT:G	donor_loss	1.0000
9:97473627:GT:G	donor_loss	1.0000
9:97473628:T:A	donor_loss	1.0000
9:97480897:T:G	donor_gain	1.0000
9:97482835:T:TA	acceptor_gain	1.0000
9:97482837:T:TA	acceptor_gain	1.0000
9:97482845:A:AG	acceptor_gain	1.0000
9:97482845:AAAG:A	acceptor_gain	1.0000

AlphaMissense

7257 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:97428556:T:G	Y31D	0.999
9:97480873:T:A	W783R	0.999
9:97480873:T:C	W783R	0.999
9:97495680:T:A	W1032R	0.999
9:97495680:T:C	W1032R	0.999
9:97495705:T:C	F1040S	0.999
9:97495708:G:C	R1041P	0.999
9:97428509:T:C	L15P	0.998
9:97464961:C:A	A521D	0.998
9:97464990:C:G	R531G	0.998
9:97464991:G:C	R531P	0.998
9:97470570:G:C	D548H	0.998
9:97470571:A:T	D548V	0.998
9:97487173:T:A	W973R	0.998
9:97487173:T:C	W973R	0.998
9:97487181:G:C	R975S	0.998
9:97487181:G:T	R975S	0.998
9:97487321:C:A	A1022D	0.998
9:97428581:T:C	I39T	0.997
9:97428644:T:A	V60D	0.997
9:97470571:A:C	D548A	0.997
9:97470648:G:C	A574P	0.997
9:97483198:C:A	A921D	0.997
9:97483333:C:A	A966D	0.997
9:97487180:G:C	R975T	0.997
9:97487180:G:T	R975M	0.997
9:97487240:G:A	G995D	0.997
9:97487327:T:A	L1024H	0.997
9:97487327:T:C	L1024P	0.997
9:97495737:G:C	A1051P	0.997

dbSNP variants (sampled 300 via entrez): RS1000012591 (9:97491050 G>A,C), RS1000085489 (9:97490473 T>C), RS1000088367 (9:97461281 G>A), RS1000141807 (9:97443161 T>G), RS1000147056 (9:97410865 A>G,T), RS1000162479 (9:97463084 C>T), RS1000184001 (9:97420536 G>A,T), RS1000293275 (9:97414984 C>CT), RS1000358674 (9:97413712 C>G), RS1000502616 (9:97461413 T>C), RS1000510117 (9:97435965 CACAT>C), RS1000517277 (9:97418064 G>T), RS1000555683 (9:97468926 A>G), RS1000567053 (9:97489258 C>G), RS1000675456 (9:97470421 C>A,T)

Disease associations

OMIM: gene MIM:611258 | disease phenotypes: MIM:613887

GenCC curated gene-disease

Disease	Classification	Inheritance
cataract 36	Strong	Autosomal recessive

Mondo (1): cataract 36 (MONDO:0013484)

Orphanet (0):

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000518	Cataract

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST008097_32	Bisphosphonate-associated atypical femoral fracture	2.000000e-06
GCST008155_7	Waist-hip ratio	6.000000e-06
GCST010002_274	Refractive error	5.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009958	response to bisphosphonate
EFO:0009960	atypical femoral fracture
EFO:0004343	waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105828 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	6
methylmercuric chloride	decreases expression	3
Tretinoin	decreases expression, increases expression	3
graphene oxide	increases expression	2
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
FR900359	decreases phosphorylation	1
alpha phellandrene	increases expression	1
trichostatin A	decreases expression, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
entinostat	increases expression	1
K 7174	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Decitabine	affects expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	increases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Caffeine	decreases phosphorylation	1
Carbamazepine	affects expression	1
Cisplatin	affects expression	1
Diclofenac	affects expression	1
Hydrogen Peroxide	affects expression	1
Lipopolysaccharides	increases expression, affects response to substance	1

ChEMBL screening assays

4 unique, capped per target: 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4034448	Binding	Inhibition of PCTAIRE2 Lysine 2 labelling site (unknown origin) at 10 uM	Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus. — Bioorg Med Chem Lett

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1HV	Abcam A-549 TDRD7 KO 1	Cancer cell line	Male
CVCL_B2QE	Abcam A-549 TDRD7 KO 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.